Baxter's Gammagard shows potential in stabilizing Alzheimer's
The first report of long-term (three-year) stabilization of Alzheimer's disease symptoms with intravenous immunoglobulin (IVIG), Gammagard from US health care firm Baxter International (NYSE: BAX), including no decline on measures of cognition, memory, daily functioning and mood, was reported this week at the Alzheimer's Association International Conference in Vancouver, Canada.
In addition, updates were given on three new presymptomatic Alzheimer's disease treatment trials that are beginning soon or in the planning stages.
Although Baxter does not hold patent rights on Gammagard, it funded the study. IVIG treatment has been used for three decades to replace antibodies in patients who do not make enough to prevent infections. Similar products are also sold by Spain’s Grifols, Australia’s CSL and Octapharma of Switzerland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze